H1 Blog

JULY 30, 2024

Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. We’re curious to see what will happen over the next 12 months and how pharma companies will respond.”

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

H1 Blog

JUNE 7, 2023

Clinical trial success is a key factor for pharma companies when designing and recruiting patients into trials. This is especially true for rare disease populations, where understanding the nuances between different patient cohorts is key to achieving positive outcomes. The Michael J.

Trials 52

Trials Clinical Trials Pharma Companies Clinical Development 52

H1 Blog

DECEMBER 11, 2024

As these standards take shape, pharma companies will adopt tools and models to reach broader and more diverse participants. Ariel Katz , CEO & Co-Founder AI will be used to combat rare diseases. Beyond diagnosis, AI will predict treatment responses, personalize therapies, and uncover new disease patterns.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Treatment 52

H1 Blog

JULY 5, 2023

To learn more about how H1 can help diversify your HCP engagement strategy, request a demo.

Clinical Trials 52

Clinical Trials Drugs Trials Drug Development 52